Cellares

Cellares is proud to be featured in Fortune, highlighting how we are revolutionizing cell therapy manufacturing. With a state-of-the-art facility in New Jersey and backing from industry leaders like Bristol Myers Squibb, we're accelerating access to life-saving cell therapies. Cellares’ scalable and cost-effective solutions have been designed to meet the needs of companies of all sizes, from early-stage biotechs with pre-clinical assets to large pharmaceutical organizations with commercialized cell therapies. Powered by advanced manufacturing technologies, including the Cell Shuttle and Cell Q, our services enable our partners to meet the total patient demand for their therapies. Are you curious to learn more about how we're shaping the future of biotech? Check out the full Fortune article here: https://lnkd.in/dDCijjcb #Biotech #CellTherapy #Innovation #Healthcare #CAR-T

🚨 Exciting News! 🚨 Cellares and Cabaletta Bio have successfully completed the proof of concept Technology Adoption Program (TAP) for the manufacturing of rese-cel (CABA-201) using Cellares’ cutting-edge Cell Shuttle™ platform. This is a major milestone in automating, reducing costs, and scaling out manufacturing for Cabaletta’s clinical-stage CAR T program targeting autoimmune diseases. We look forward to continuing our work with Cabaletta to complete the activities required to enable the use of the Cell Shuttle in clinical trials and support the delivery of these potentially curative autologous therapies to more patients. Through TAP, the automated Cell Shuttle simultaneously produced multiple batches of rese-cel, while meeting predefined quality standards. 🌍 The potential of Cellares’ global IDMO Smart Factory network—planned for the US, Europe, and Japan—offers Cabaletta Bio the ability to scale rapidly and efficiently, meeting patient demand for diseases like myositis, scleroderma, and lupus nephritis. We’re proud to be shaping a future where innovative platforms like the Cell Shuttle can bring hope and curative potential to patients worldwide by enabling small and large cell therapy developers to meet the total patient demand for their cell therapies. 💪🔬 Read the full release here: https://lnkd.in/dA8mcBKf #Biotech #CellTherapy #Innovation #CAR-T

Patients are dying on waitlists – 20% pass away before receiving life-saving cell therapies. I interviewed Fabian Gerlinghaus, CEO of Cellares, who's set out to change that - and is taking big pharma by storm:

Cellares’ CEO and Co-founder, Fabian Gerlinghaus, will be presenting at the Precision Medicine World Conference at the Santa Clara Convention Center! Save the date for February 6th at 2:15pm PT and join his session, “Scaling Cell Therapy Manufacturing to Treat Rapidly Expanding Patient Populations.” This insightful presentation will address critical challenges in cell therapy manufacturing, including how limited capacity and reliance on manual methods have created devastating bottlenecks—resulting in up to 20% of eligible patients losing their lives while waiting for treatment. As trial recruitment becomes more competitive and treatment sites less tolerant to staying idle while waiting for production slots, we view it as imperative that developers, small and large, adopt a platform that offers the flexibility to manufacture batches on demand at low volumes and that seamlessly scales to meet commercial-scale production volumes. Cell therapy developers that don’t overcome these challenges now risk a potentially crippling disadvantage as their therapies progress through the clinical pipeline and towards commercialization. This session is essential for anyone passionate about addressing the pressing challenges in cell therapy manufacturing and ensuring patients receive the life-saving treatments that they need. We can’t wait to see you there and are looking forward to a meaningful discussion about the future of cell therapy manufacturing! #CellTherapy #Biotech #AdvancedTherapiesWeek #Innovation #PMWC25

We’re pleased to share that Cellares will be attending the Precision Medicine World Conference from February 05–07 in Santa Clara, CA! This event offers a great opportunity to connect with some of the brightest minds and leaders in the cell and gene therapy community. Visit us at booth A310 to learn how Cellares' IDMO Smart Factories—powered by our automated cell therapy manufacturing platforms, the Cell Shuttle and the Cell Q—can scale to meet your manufacturing needs, whether early phase, late phase, or commercial. We’re looking forward to exchanging ideas, building fruitful collaborations, and shaping the future of cell therapies together. See you in Santa Clara! #PMWC25 #CellTherapy #CARTTherapy #Automation

Arturo Araya, Cellares EVP of Commercialization, will be presenting at Phacilitate’s Advanced Therapies Week in Dallas. Mark your calendars for January 22nd at 10am CT and don’t miss his session titled “The Coming Patient Treatment Crisis.” This presentation will highlight how critical challenges in manufacturing capacity are resulting in up to 20% of eligible patients dying on waitlists due to bottlenecks caused by manual manufacturing methods. Adding to this access challenge, patient populations are expected to increase significantly in the coming years, as therapies are being approved earlier and showing promise in new indications, such as autoimmune diseases. Therapy developers that do not proactively address these challenges through automated, scalable solutions will have a potentially crippling competitive disadvantage. This is a must-attend session for anyone passionate about overcoming current challenges in cell therapy manufacturing and ensuring patients have access to the treatments they desperately need. We hope to see you there and look forward to an engaging conversation about the future of cell therapy manufacturing together. 🌟 #CellTherapy #Biotech #AdvancedTherapiesWeek #Innovation #ATW25

We are pleased to announce that Cellares will be attending Phacilitate’s Advanced Therapies Week Jan 20 - Jan 22 at the Kay Bailey Hutchison Convention Center in Dallas, Texas. This event is a fantastic opportunity to connect with innovators and leaders in the advanced therapies community.   Be sure to stop by our booth, # 754, to learn more about how Cellares' IDMO Smart Factories leveraging our automated cell therapy manufacturing platforms, the Cell Shuttle and the Cell Q, can help you meet the total demand for your cell therapies while reducing costs. We look forward to sharing ideas, building partnerships, and defining the future of cell therapies together. See you in Dallas! 🌟 #ATW2025 #AdvancedTherapiesWeek #Phacilitate #CellTherapy

We are pleased to announce that Cellares has won the Fierce Innovation Award in the Technology Innovation category for our Cell Shuttle and Cell Q platforms! 🏆 The Cell Shuttle is an automated, end-to-end cell therapy manufacturing platform that integrates all of the technologies required for cell therapy manufacturing. The Cell Q is an automated QC work cell that integrates best-in-class, off-the-shelf instrumentation that is capable of automating the majority of cell therapy in-process and release testing assays. Combined, these technologies unblock the upstream and downstream cell therapy manufacturing bottlenecks, which will enable developers to meet the total patient demand for their cell therapies. These award-winning technologies are deployed throughout our network of Integrated Development and Manufacturing Organization (IDMO) Smart Factories, enabling us to produce 10 times as many cell therapy batches as conventional CDMOs, with up to a 50% reduction in batch price. This recognition highlights our commitment to transforming cell therapy manufacturing through innovative solutions and cutting-edge technology. We are proud to be on a mission to accelerate access to life-saving cell therapies by enabling developers to meet the total patient demand for their cell therapies. A big thank you to those who voted for our technologies, our team, and our partners for making this possible! Check out the full list of winners here ⬇️ https://lnkd.in/dMkUV2zT #Biotechnology #CellTherapy #Innovation #FierceInnovationAwards #FierceLifeSciencesInnovationAwards

Cellares Co-Founder and CEO, Fabian Gerlinghaus, was recently interviewed by @Onyx Newsroom’s Adil Ali, MD to be included in Fortune's Vital Signs special report, publishing on December 1st. In this interview, Fabian covers the inception of Cellares: recognizing that current manual cell therapy manufacturing paradigms were not designed to be scalable to meet the needs of commercial cell therapy manufacturing. Along with prohibitive manufacturing costs, this has led to the tragic outcome of eligible patients dying on the waitlists for these potentially curative therapies. The interview then covers the development of the technologies that Cellares has created to overcome these bottlenecks - the Cell Shuttle and the Cell Q - the world’s first automated, end-to-end cell therapy manufacturing and QC platforms that integrate all of the technologies necessary to manufacture and perform in-process and release QC for cell therapies. When deployed throughout Cellares’ network of Integrated Development and Manufacturing Organization (IDMO) Smart Factories, these technologies will enable cell therapy developers to meet the total patient demand for their cell therapies. Read the full interview here to learn about this and more: https://lnkd.in/gegWpvqM

Cellares CEO and Co-Founder, Fabian Gerlinghaus, will present at the Biomanufacturing World Summit on Thursday, November 21st at 7:45 AM PT. His talk, "The Coming Patient Treatment Crisis," will explore critical challenges patients face in accessing cell therapies. Don’t miss this opportunity to hear from a prominent biotech leader and discover how Cellares’ pioneering technological approach to high-throughput manufacturing will enable cell therapy developers to meet the full demand for their life-saving treatments. For further details on Cellares' cutting-edge automated cell therapy manufacturing technology, visit cellares.com/technology.